Revolutionizing Cancer Treatment in India: The Impact of Chinese-Origin Drugs
How Chinese pharma helping Indian patients with cutting edge therapies
The Economic Times
Image: The Economic Times
Chinese-origin cancer drugs are transforming oncology in India by significantly reducing the costs of immunotherapy. With partnerships between Indian and Chinese pharmaceutical companies, treatments that once cost up to ₹500,000 (approximately $6,000 USD) per session are now available for around ₹50,000 (approximately $600 USD), making them accessible to more patients.
- 01Chinese-origin cancer drugs are reducing immunotherapy costs in India.
- 02The price of immunotherapy has dropped from ₹500,000 to ₹50,000 per session.
- 03Indian pharmaceutical companies are entering billion-dollar partnerships with Chinese firms.
- 04Patients are responding positively to these new treatment options.
- 05The collaboration is reshaping cancer treatment accessibility in India.
Advertisement
In-Article Ad
A significant shift is occurring in the field of oncology in India, driven by the introduction of Chinese-origin cancer drugs. These treatments are making immunotherapy much more affordable, with costs plummeting from ₹500,000 (approximately $6,000 USD) per session to just ₹50,000 (approximately $600 USD). This change is facilitated by partnerships between Indian pharmaceutical companies, such as Glenmark, Dr. Reddy’s, and Intas, and their Chinese counterparts, leading to billion-dollar deals aimed at expanding access to these therapies. As a result, doctors are increasingly prescribing these affordable options, and patients are showing positive responses to the treatments. This collaboration between India and China is not only transforming the landscape of cancer treatment but also ensuring that more patients receive the care they need.
Advertisement
In-Article Ad
The availability of affordable cancer treatments means that more patients in India can access life-saving therapies, potentially improving survival rates and quality of life.
Advertisement
In-Article Ad
Reader Poll
Do you think affordable cancer treatment options should be prioritized in India?
Connecting to poll...
Read the original article
Visit the source for the complete story.